VolitionRx Highlights $23 B Capture-Seq™ Opportunity, Q4 2026 Lung Reimbursement and $5 M Cat Test Milestone
VolitionRx submitted a peer-review paper on its Capture-Seq™ method underscoring a $23 billion cancer detection opportunity and achieved 100% specificity in its Nu.Q® Vet Feline lymphoma test with a $5 million milestone payment. Lung cancer reimbursement in France targets use by Q4 2026; the Nu.Q® NETs assay joins a $7.3 million sepsis detection program.
1. Capture-Seq™ Platform Breakthrough
VolitionRx submitted a peer-review paper on its Capture-Seq™ method showcasing novel biomarkers and a potential $23 billion annual cancer detection market, attracting interest from major diagnostic partners for licensing and commercial development.
2. Lung Cancer Reimbursement Plans
The company is preparing its Nu.Q® Cancer assay reimbursement submission in France with support from Hospices Civils de Lyon, aiming for routine clinical use by Q4 2026 to drive adoption and revenue growth in its human diagnostics division.
3. Veterinary Feline Lymphoma Milestone
In a feline study, the Nu.Q® Vet Feline assay achieved 100% specificity and over 80% detection of lymphoma, triggering a $5 million milestone payment and expanding the addressable veterinary oncology market.
4. Sepsis Assay and Licensing Momentum
The Nu.Q® NETs assay has been included in a $7.3 million sepsis detection program in France, and VolitionRx is in active discussions with approximately ten global diagnostic leaders to secure licensing agreements for its platform technologies.